SLC5A2 and dementia: Regarding SGLT-2 inhibitors, dapagliflozin showed the lowest risk (aHR 0.67 [95% CI 0.53–0.84]), followed by empagliflozin (aHR 0.78 [95% CI 0.69–0.89]), whereas no relationship between canagliflozin and dementia was noted (aHR 0.96 [95% CI 0.80–1.16]) [87].